ada standards of care 2025 obesity pharmacotherapy glp-1 for management in adults: clinical practice guideline update The American Diabetes Association Releases

Versatile and easy to brew, ECOTEAS unsmoked yerba mate elevates metabolism and mood with balanced nutrition and stimulation

The statements have not been evaluated by the Food and Drug Administration (FDA)

A provider-guided tirzepatide microdosing program designed to support metabolic health, cardiovascular risk reduction, and sustainable weight managementenhanced with glycine for optimized performance and recovery.

ANZCA and peak diabetes, obesity and gastroenterological bodies have produced an updated set of clinical practice recommendations for patients using GLP-1 receptor agonists and dual GLP-1/GIP receptor co-agonists

The BALANCE program was intended to cover weight-loss drugs for Medicaid beneficiaries, but is delayed

With over 50% of GLP-1 users discontinuing due to cost and 36% due to side effects, Nooms low and slow titration strategy could offer a more sustainable path to weight loss